Onfi Shortage: What Providers and Prescribers Need to Know in 2026

For neurologists, epileptologists, and other providers prescribing clobazam (Onfi, Sympazan), the ongoing supply challenges represent a genuine clinical problem. Patients with Lennox-Gastaut syndrome (LGS) and other refractory epilepsies depend on uninterrupted clobazam access for seizure control, and supply gaps can have serious consequences. This clinical overview covers the 2026 shortage landscape, the risks of abrupt discontinuation, available alternatives, and tools to help your patients maintain access.

Current Availability Landscape for Clobazam in 2026

As of 2026, clobazam availability remains inconsistent across formulations and regions. The FDA's Drug Shortages database may not always reflect active listings, but patient and pharmacy reports consistently indicate localized supply gaps:

• Generic clobazam tablets (10 mg, 20 mg): Available from multiple manufacturers, though intermittent shortages at the pharmacy level persist. Availability varies significantly by region and pharmacy type.
• Generic clobazam oral suspension (2.5 mg/mL): Most affected by supply disruptions. May be unavailable for extended periods at many pharmacies. Creates particular challenges for pediatric patients unable to swallow tablets.
• Brand Onfi: Limited availability; largely replaced by generics in most markets.
• Sympazan oral film (5 mg, 10 mg, 20 mg): Available, but may require specialty pharmacy channels and prior authorization. Can serve as a useful backup when tablets and suspension are unavailable.

Independent and specialty pharmacies tend to have more consistent stock than large chain pharmacies. Advising patients to establish a relationship with an independent pharmacy, particularly one serving neurology or pediatric populations, can be an important proactive step.

Drivers of the Clobazam Supply Problem

The persistence of clobazam supply challenges is explained by several structural factors:

• Niche patient population: LGS is a rare condition; the clobazam market is small relative to other generics, resulting in a limited number of API and finished-dose manufacturers.
• DEA Schedule IV constraints: Annual DEA production quotas limit how quickly manufacturers can ramp up output when demand spikes or another producer exits the market.
• Manufacturing complexity: The oral suspension is particularly challenging to produce at scale, with quality control requirements that reduce the number of capable manufacturers.

Clinical Risks of Clobazam Discontinuation

For providers, understanding the clinical risk profile of abrupt clobazam discontinuation is critical for patient counseling and prescribing contingency plans. Key risks include:

• Rebound seizures: Abrupt discontinuation can trigger seizures more severe than pre-treatment baseline in patients with LGS.
• Status epilepticus: Prolonged, life-threatening seizures are a known risk with abrupt benzodiazepine discontinuation.
• Benzodiazepine withdrawal syndrome: Hallucinations, tremor, agitation, insomnia, and autonomic instability can occur, typically beginning within 24–48 hours of the last dose.

Per FDA prescribing information, if a dose reduction or discontinuation is necessary, clobazam should be tapered by reducing the total daily dose by 5–10 mg/day on a weekly basis until discontinued. When a supply disruption is anticipated, early communication with the patient and proactive planning are essential.

CYP2C19 Pharmacogenomics: A Clinical Consideration

Clobazam is extensively metabolized by CYP2C19 to its active metabolite, N-desmethylclobazam. Approximately 2–5% of Caucasians and 15–20% of Asian patients are CYP2C19 poor metabolizers, resulting in significantly higher active metabolite levels at equivalent doses. When initiating therapy or adjusting doses, poor metabolizers should start at 5 mg/day regardless of body weight and titrate more slowly.

Additionally, cannabidiol (Epidiolex), which is increasingly co-prescribed in LGS patients, is a CYP2C19 inhibitor. When CBD and clobazam are used together, clobazam dose reduction may be necessary to avoid toxicity from elevated metabolite levels.

Therapeutic Alternatives When Clobazam Is Unavailable

When clobazam is unavailable and a patient is at risk of running out, the following alternatives may be considered based on clinical presentation:

• Clonazepam (Klonopin): Closest pharmacologic alternative; 1,4-benzodiazepine; more sedating; widely available at $10–$30/month; requires dose conversion calculation.
• Rufinamide (Banzel): FDA-approved for LGS; different mechanism (sodium channel); no withdrawal risk; well-tolerated.
• Valproate/Valproic acid: Broad-spectrum; FDA-approved for multiple seizure types; monitor for hepatotoxicity, pancreatitis, and teratogenicity.
• Lamotrigine (Lamictal): Widely used in LGS; requires careful titration to minimize SJS risk; interactions with valproate affect dosing.

Cost and Access Considerations for Patients

For patients struggling with cost, several resources are available:

• Generic clobazam: $30–$150 cash price; $50–$90 with GoodRx or SingleCare discount cards. Recommend the generic when brand Onfi is prescribed.
• Lundbeck patient assistance program: Available for eligible uninsured or underinsured patients; contact 1-800-455-1141 or visit onfi.com.
• Epilepsy Foundation: Maintains medication access resources and can connect patients with assistance programs.

How medfinder Can Help Your Patients

medfinder offers a provider-facing tool that helps your patients locate clobazam at nearby pharmacies. Rather than spending time troubleshooting pharmacy availability during office visits, you can direct patients to medfinder.com/providers where your team can help patients search for available supply. This is particularly valuable for LGS families who are managing complex polypharmacy regimens and cannot afford gaps in seizure medication.

Proactive Prescribing Strategies

Consider implementing these practices for clobazam-dependent patients:

• Educate patients at every visit to refill 7–10 days before running out
• Consider Sympazan as a backup formulation, especially for patients with frequent tablet supply issues
• Document a contingency plan in the chart: what to do if clobazam becomes unavailable and what the temporary alternative would be
• Recommend patients work with an independent or specialty pharmacy rather than large retail chains
• Consider 90-day supplies for patients on stable clobazam regimens where state law and DEA regulations permit